Syndrome de l’intestin irritable : aspects évolutifs

Varannes, Stanislas Bruley des

doi:10.1016/s0399-8320(09)71529-5

Gastroentérologie Clinique et Biologique

2009

DOI: 10.1016/s0399-8320(09)71529-5

|View full text |Cite

Syndrome de l’intestin irritable : aspects évolutifs

Stanislas Bruley des Varannes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2014

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contribution of the psychological profile, particularly regarding anxious-depressive components (even if relatively modest), is significantly associated with higher symptom severity and a less favorable course, as reflected by a higher number of clinical visits, more days off work, and increased use of drugs (including OTC medicines) (11). As with migraine, arthralgia, chronic low-back pain, diabetic neuropathy and fibromyalgia, numeric scales to quantify abdominal pain in patients with IBS help to objectively assess syndrome severity and facilitate therapy response monitoring (12).…”

mentioning

confidence: 99%

Measuring irritable bowel syndrome severity: What for and how?

Gil-Borrás

Pla

2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is the most common cause of consultation in the clinical practice of gastroenterology, and a significant health issue given its chronic nature and interference with health-related quality of life (HRQOL), which patients perceive as moderate to severe. It is characterized by abdominal pain and distension associated with disordered bowel habits (diarrhea, constipation, alternating habit) that persist or relapse for many years, starting during early youth in a proportion of patients. In 20-30% of cases disease onset is related to a recent history of acute, usually bacterial gastroenteritis. It allegedly affects 11-15% of the adult population -depending on the various diagnostic criteria used-mainly between 18 and 65 years of age, and is 2-3 times more common in women than in men, albeit this is not the case in all countries (1-3). This is a chronic disorder and fewer than 10% of patients remain asymptomatic at ten years after diagnosis. While the disorder does not impair patient survival, its relapsing character and severe impact on all HRQOL dimensions, primarily vitality, work, leisure, traveling, and social interactions,

show abstract

mentioning

confidence: 99%

Measuring irritable bowel syndrome severity: What for and how?

Gil-Borrás

Pla

2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

Le syndrome de l’intestin irritable : toujours d’actualité

Mion

Ducrotté

2009

Gastroentérologie Clinique et Biologique

View full text Add to dashboard Cite

Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review

Triantafillidis¹,

Malgarinos²

2014

CEG

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder characterized by abdominal pain or discomfort and altered bowel habits. The disease affects a large part of the world population. The clinical course is mostly characterized by a cyclic recurrence of symptoms. Therefore, IBS patients should receive, as an initial therapeutic approach, a short course of treatment, and long-term treatment should be reserved for those patients with recurrent symptoms. The available clinical trials show that significant improvement of the symptoms over placebo could be achieved with various drugs, although this improvement is frequently time dependent and with high relapse rates after the cessation of the treatment. In a proportion of patients, clinically obvious relapse could appear long after stopping the treatment. Some of the available pharmacologic agents, including otilonium bromide (OB), are able to significantly prolong the time to the appearance of relapse, compared with placebo. As a consequence, some authors suggest that a cyclic treatment could be of benefit. Antispasmodic drugs have been used for many years in an effort to control the symptoms of IBS. OB is a poorly absorbed spasmolytic drug, exerting significantly greater control of the symptoms of IBS compared with placebo. Recent data suggest that the drug could effectively be used for the long-term management of patients with IBS. The aim of this review is to provide the reader with an evidence-based overview of the efficacy and tolerability of OB in the long-term management of IBS patients, based on the results of the clinical trials published so far.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Syndrome de l’intestin irritable : aspects évolutifs

Cited by 3 publications

References 43 publications

Measuring irritable bowel syndrome severity: What for and how?

Measuring irritable bowel syndrome severity: What for and how?

Le syndrome de l’intestin irritable : toujours d’actualité

Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review

Contact Info

Product

Resources

About